Repaglinide
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Repaglinide |
| DrugBank ID | DB00912 |
| Brand Names (EU) | NovoNorm, Repaglinide Krka |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 98.77% |
Approved Indication (EMA)
Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in type 2 diabetes patients who are not satisfactorily controlled on metformin alone. Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | opsismodysplasia | 98.77% | DL |
| 2 | diabetes mellitus (disease) | 98.56% | DL |
| 3 | classic stiff person syndrome | 98.48% | DL |
| 4 | focal stiff limb syndrome | 98.48% | DL |
| 5 | thiamine-responsive dysfunction syndrome | 98.47% | DL |
| 6 | drug-induced localized lipodystrophy | 97.80% | DL |
| 7 | centrifugal lipodystrophy | 97.65% | DL |
| 8 | pressure-induced localized lipoatrophy | 97.61% | DL |
| 9 | pancreatic agenesis | 97.58% | DL |
| 10 | idiopathic localized lipodystrophy | 97.43% | DL |
| 11 | autoimmune oophoritis | 93.59% | DL |
| 12 | type 1 diabetes mellitus | 92.69% | DL |
| 13 | cholangiocarcinoma, susceptibility to | 64.02% | DL |
| 14 | mitral valve prolapse, myxomatous | 60.99% | DL |
| 15 | hemoglobin C-beta-thalassemia syndrome | 60.17% | DL |
| 16 | woolly hair, autosomal recessive 3 | 59.26% | DL |
| 17 | hypercarotenemia and vitamin A deficiency, autosomal recessive | 59.07% | DL |
| 18 | congenital temporomandibular joint ankylosis | 58.61% | DL |
| 19 | obsolete breast fibroadenosis | 58.56% | DL |
| 20 | atrial flutter (disease) | 58.23% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.